Recent 8.5% Pullback Isn't Enough to Hurt Long-term GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Shareholders, They're Still up 74% Over 3 Years
Recent 8.5% Pullback Isn't Enough to Hurt Long-term GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Shareholders, They're Still up 74% Over 3 Years
While GuangYuYuan Chinese Herbal Medicine Co., Ltd. (SHSE:600771) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 11% in the last quarter. But that doesn't change the fact that the returns over the last three years have been pleasing. To wit, the share price did better than an index fund, climbing 74% during that period.
而当广域源中草药有限公司。(上海证券交易所:600771)股东可能总体上很满意,该股最近表现不是特别好,上个季度股价下跌了11%。但这并不能改变过去三年回报一直令人满意的事实。换言之,该公司股价表现好于指数基金,在此期间攀升了74%。
In light of the stock dropping 8.5% in the past week, we want to investigate the longer term story, and see if fundamentals have been the driver of the company's positive three-year return.
鉴于该公司股价在过去一周下跌了8.5%,我们希望调查更长期的情况,看看基本面因素是否是该公司三年来正回报的驱动因素。
See our latest analysis for GuangYuYuan Chinese Herbal Medicine
请看我们对广域园中草药的最新分析
Because GuangYuYuan Chinese Herbal Medicine made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
由于光裕源中药在过去12个月中出现亏损,我们认为市场可能更关注营收和营收增长,至少目前是这样。一般来说,没有利润的公司预计每年都会有收入增长,而且增长速度很快。这是因为快速的收入增长可以很容易地推断出预期利润,通常是相当大的规模。
GuangYuYuan Chinese Herbal Medicine's revenue trended up 0.1% each year over three years. Considering the company is losing money, we think that rate of revenue growth is uninspiring. In that time the share price is up 20% per year, which is not unreasonable given the revenue growth. Ultimately, the important thing is whether the company is trending to profitability. In this sort of situation it can be worth putting the stock on your watchlist. If it can become profitable, then even moderate revenue growth could grow profits quickly.
在过去的三年里,光裕源中药的收入每年都在增长0.1%。考虑到该公司正在亏损,我们认为收入增长速度并不令人振奋。在此期间,该公司股价每年上涨20%,考虑到收入的增长,这并不是不合理的。归根结底,重要的是该公司是否正在走向盈利。在这种情况下,将这只股票放在你的观察名单上是值得的。如果它能够实现盈利,那么即使是温和的收入增长也可能迅速增长利润。
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
下图显示了收益和收入随时间的变化情况(如果您点击该图,您可以看到更多详细信息)。
Take a more thorough look at GuangYuYuan Chinese Herbal Medicine's financial health with this free report on its balance sheet.
更透彻地看广域苑中草药的财务健康状况免费报告其资产负债表。
A Different Perspective
不同的视角
The total return of 4.6% received by GuangYuYuan Chinese Herbal Medicine shareholders over the last year isn't far from the market return of -4.8%. The silver lining is that longer term investors would have made a total return of 4% per year over half a decade. If the fundamental data remains strong, and the share price is simply down on sentiment, then this could be an opportunity worth investigating. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with GuangYuYuan Chinese Herbal Medicine , and understanding them should be part of your investment process.
光裕源中草药股东过去一年的总回报率为4.6%,与-4.8%的市场回报率相距不远。一线希望是,较长期投资者将在五年内实现每年4%的总回报率。如果基本面数据保持强劲,股价只是因情绪低迷而下跌,那么这可能是一个值得研究的机会。我发现,把股价作为衡量企业业绩的长期指标是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。例如,考虑一下无处不在的投资风险幽灵。我们已经确定了1个警告信号与光裕苑中草药合作,了解它们应该是您投资过程的一部分。
But note: GuangYuYuan Chinese Herbal Medicine may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但请注意:广域源中草药可能不是买入的最佳股票。所以让我们来看看这个免费过去有盈利增长(以及进一步增长预测)的有趣公司名单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。